- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02266511
Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride in Healthy Male Subjects
October 16, 2014 updated by: Boehringer Ingelheim
A Single-dose, Randomized, Two-treatment, Two-period, Open-label, Crossover Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride 0.4-mg Capsules in Healthy Male Subjects
The objective of this study is to determine the bioequivalence of two batches of Flomax® 0.4 mg capsules in healthy male subjects.
One is a commercial scale batch produced at the Nishine facility, and the other is a batch, of equal size, produced at the Norman II facility
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Provide written informed consents, as evidenced by signature on an Informed Consent Form approved by the investigational review board (IRB) following a full explanation of the nature and purpose of the study
- Be a healthy male of any race between 18 and 40 years of age
- Have a body weight within 10 % of normal for sex, height, and frame as specified by the Body Weight Nomogram for Inclusion/Exclusion Criteria
- Have no clinically significant abnormalities o the basis of medical history, physical examination, and vital signs with no significant orthostatic blood pressure change, which is defined as no more than a 20 mm Hg drop in systolic blood pressure on assuming and maintaining the standing position for 3 minutes after being supine for at least 5 minutes. There should be no clinically significant symptoms associated with the orthostatic blood pressure testing procedure
- Have cardiovascular system that is within normal limits based on history, physical examination, and a 12-lead electrocardiogram (ECG)
- Have a negative test for ethanol by breathalyzer
- Have the ability to understand the requirements of the study, agree to abide by the study restrictions, and agree to return for the required assessments
Exclusion Criteria:
- Require ambulatory assistance (e.g., canes or walkers)
- Have a history of a "first dose hypotensive episode" upon starting therapy with an alpha-blocker
- Have a history of a pathological fall (unintentional change in body position) during the last year occurring under circumstances in which normal homeostatic mechanisms would ordinarily maintain stability or syncope
- Have any medical or laboratory abnormalities (liver function tests, blood urea nitrogen, and creatinine should not be outside the reference range for the clinical laboratory). Any subject who enters into the study with laboratory abnormalities must be approved by the Medical Monitor prior to enrollment
- Have abnormal alpha-1-acid glycoprotein values (i.e., values greater than 120 mg/dL)
- Have any history of acute angina attacks during the prior 6 months
- Have any abnormality of the ECG or a history of a documented myocardial infarction (electrocardiographic changes, serum enzymes increases, and hospitalization) during the prior 6 months, or evidence of any myocardial infarction on an ECG
- Have a New York Heart Association's Functional Classification of Heart Failure Class I, II, III, or IV
- Have a prior history of endocarditis
- Use any prescription medications within 2 weeks of dosing, or over-the-counter concomitant therapies with the exception of vitamins, dietary supplements, and acetaminophen within 7 days of dosing
- Have used an investigational drug within 1 month (30 days) of the Screening Period visit
- Donated blood within 1 month of entering study
Have a known history of any of the following:
- Clinically significant renal disease (renal dysfunction; i.e., creatinine greater than or equal to 2.0 mg/dL)
- Severe cardiovascular disease (coarctation of the aorta, severe cardiac failure, second or third degree heart block, or severe angina)
- Pulmonary disease (chronic lung disease or emphysema of a degree that could cause functional abnormalities of the right heart)
- Have acute illness (e.g., acute upper respiratory infection) within 2 weeks prior to the start of the study
- Have any medical condition that might interfere with either the absorption, distribution, metabolism, or excretion of tamsulosin
- Have a history of any illness or allergy that, in the opinion of the Investigator, might confound the results of the study or pose additional risk in administering Flomax® to the subject
- Have a history of liver disease or any physical findings suggestive of liver disease
- Have smoked within the last 3 months or be known as or be suspected as an alcohol abuser or illicit drug user within the past year, or have a positive urine drug screen
- Exhibit, in the opinion of the Investigator, the signs or symptoms of an immunodeficiency syndrome, whether spontaneously acquired, congenital, or iatrogenic (These syndromes are characterized by unusual susceptibility to infection [bacterial, viral, or fungal], the occurrence of autoimmune disease, and lymphoreticular malignancies)
Have calculated creatinine clearance less than 90 mL/min based upon the following formula:
- Creatinine Clearance = (140 - age in years) (weight in kg) / (72) (serum creatinine)
- Have a history of cancer except for nonmelanoma skin cancer treated by excision
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence 1
Flomax®, Nishine facility followed by Flomax®, Norman II facility
|
Other Names:
Other Names:
|
Experimental: Sequence 2
Flomax®, Norman II facility followed by Flomax®, Nishine facility
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the concentration-time curve of the analyte in plasma at different time points (AUC)
Time Frame: Up to 48 h after drug administration
|
Up to 48 h after drug administration
|
Maximum concentration of the analyte in plasma (Cmax)
Time Frame: Up to 48 h after drug administration
|
Up to 48 h after drug administration
|
Time to reach the maximum concentration of the analyte in plasma (tmax)
Time Frame: Up to 48 h after drug administration
|
Up to 48 h after drug administration
|
Elimination half-life (t1/2)
Time Frame: Up to 48 h after drug administration
|
Up to 48 h after drug administration
|
Terminal elimination rate constant of the analyte in plasma (λz)
Time Frame: Up to 48 h after drug administration
|
Up to 48 h after drug administration
|
Number of participants with clinically relevant changes in laboratory values
Time Frame: Up to day 3 after last drug administration
|
Up to day 3 after last drug administration
|
Number of participants with clinically relevant changes in vital signs (heart rate, orthostatic blood pressure, weight, temperature, respiration rate)
Time Frame: Up to day 3 after last drug administration
|
Up to day 3 after last drug administration
|
Number of participants with adverse events
Time Frame: Up to day 3 after last drug administration
|
Up to day 3 after last drug administration
|
Number of participants with clinically relevant changes in ECG
Time Frame: Up to day 3 after last drug administration
|
Up to day 3 after last drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 1999
Primary Completion (Actual)
September 1, 1999
Study Registration Dates
First Submitted
October 16, 2014
First Submitted That Met QC Criteria
October 16, 2014
First Posted (Estimate)
October 17, 2014
Study Record Updates
Last Update Posted (Estimate)
October 17, 2014
Last Update Submitted That Met QC Criteria
October 16, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 527.22
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Flomax®, Norman II facility
-
Umeå UniversitySwedish Council for Working Life and Social Research; Jämtland County Council... and other collaboratorsCompleted
-
Zimmer BiometCompletedDegenerative Disc Disease | Degenerative SpondylolisthesisUnited States
-
Johnson & Johnson Surgical Vision, Inc.CompletedCataract | Corneal AstigmatismUnited States
-
Irmandade Santa Casa de Misericórdia de Porto AlegreFederal University of Rio Grande do SulCompletedHeart; Dysfunction Postoperative, Cardiac SurgeryBrazil
-
GlaxoSmithKlineCompleted
-
Merck Sharp & Dohme LLCCompletedMeasles | Rubella | Mumps | VaricellaFrance, Italy
-
Neuravi Inc.CompletedIschemia | StrokeIreland, United States, Belgium, Germany
-
Johnson & Johnson Surgical Vision, Inc.CompletedCataract | Corneal AstigmatismUnited States
-
Niguarda HospitalNeuravi LimitedRecruitingAcute Ischemic StrokeItaly
-
Teva Pharmaceuticals USACompleted